News: Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

63.67USD
3:19pm EDT
Price Change (% chg)

$-0.70 (-1.09%)
Prev Close
$64.37
Open
$64.01
Day's High
$64.07
Day's Low
$63.49
Volume
378,293
Avg. Vol
1,209,444
52-wk High
$65.65
52-wk Low
$47.53

Search Stocks
Select another date:

Thu, Jul 24 2014

Lilly beats forecasts, vows to remain independent

- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.

BRIEF-Lilly says would not pursue tax inversions as "primary driver" of potential deals

July 24 - Eli Lilly and Co : * CFO, in conference call with investors, says company would not pursue tax inversions as "primary driver" of any

CORRECTED-UPDATE 2-Lilly beats forecasts, vows to remain independent

(Corrects 10th paragraph to show Pfizer bought Warner Lambert, Pharmacia and Wyeth (not Pfizer)

Spooked by probes, pharma executives ask: should I leave China?

SHANGHAI - China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months. Others are thinking of going for good.

Spooked by probes, pharma executives ask: should I leave China?

* Charges against GSK's Mark Reilly shocked business community

Sanofi, Lilly pursue Cialis over-the-counter approval

PARIS - Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in a statement on Wednesday.

Sanofi, Lilly pursue Cialis over-the-counter approval

PARIS, May 28 - Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in a statement on Wednesday.

UPDATE 1-A bitter pill as China crackdowns squeeze pharma margins

SHANGHAI, May 25 - A crackdown on corruption and pricing in China's fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over.

RPT-A bitter pill as China crackdowns squeeze pharma margins

(Repeats article first published on Sunday. No changes to text.)

A bitter pill as China crackdowns squeeze pharma margins

SHANGHAI - A crackdown on corruption and pricing in China's fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over.

Select another date:
Search Stocks